Rhaeos Funding & Investors

Evanston, IL

Rhaeos has developed FlowSense, a noninvasive wearable platform technology initially targeting hydrocephalus, a life threatening neurological condition, that affects over 1M Americans today. This $2B/yr problem is treated with surgically implanted shunts which fail half the time. CT and Xrays are used for diagnosis, but are often inconclusive and expose patients to radiation. There is no easy, inexpensive way to monitor shunts until now. Rhaeos is developing FlowSense, a bandage sized sensor that goes on the skin over shunt to assess flow in the hospital and home. This FDA breakthrough designated class II device is supported by a multidisciplinary team with significant start up experience and multiple regulatory approvals.